يعرض 51 - 60 نتائج من 308 نتيجة بحث عن '"Philipp Le Coutre"', وقت الاستعلام: 0.93s تنقيح النتائج
  1. 51
    Poster: CML-413: Asciminib Provides Durable Responses and a Favorable Safety Profile in Patients with Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) with the T315I Mutation in a Phase 1 Study

    المؤلفون: Jorge E. Cortes, Timothy P. Hughes, Michael J. Mauro, Andreas Hochhaus, Delphine Réa, Yeow-Tee Goh, J.J.W.M. Janssen, Michael C. Heinrich, Moshe Talpaz, Gabriel Etienne, Massimo Breccia, Michael Deininger, Philipp le Coutre, Fabian Lang, Fotis Polydoros, Silvia Cacciatore, Laura Stenson, Dong-Wook Kim

    المصدر: Clinical Lymphoma Myeloma and Leukemia. 21:S224

    مصطلحات موضوعية: Cancer Research, Oncology, Hematology

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::7ac94ff395393485a146a96dd9ee5fb5Test
    https://doi.org/10.1016/s2152-2650Test(21)01409-9


    أضف إلى المفضلة
  2. 52
    دورية أكاديمية
    Original Articles Impact of additional chromosomal aberrations and BCR-ABL kinase domain mutations on the response to nilotinib in Philadelphia chromosome-positive chronic myeloid leukemia

    المؤلفون: Theo D Kim, Seval Türkmen, Michaela Schwarz, Gökben Koca, Hendrik Nogai, Christiane Bommer, Bernd Dörken, Peter Daniel, Philipp Le Coutre

    المساهمون: The Pennsylvania State University CiteSeerX Archives

    المصدر: http://www.haematologica.org/content/haematol/95/4/582.full.pdfTest.

    وصف الملف: application/pdf

    العلاقة: http://citeseerx.ist.psu.edu/viewdoc/summary?doi=10.1.1.1069.1007Test; http://www.haematologica.org/content/haematol/95/4/582.full.pdfTest

    الإتاحة: http://www.haematologica.org/content/haematol/95/4/582.full.pdfTest

    View record in BASE

    أضف إلى المفضلة
  3. 53
    Retro-Prospective Observational Study on the Risk of Progression in Chronic Phase-Chronic Myeloid Leukemia (CML) Patients Eligible for Tyrosine Kinase Inhibitor Discontinuation (TFR-PRO)

    المؤلفون: Sarit Assouline, Philipp le Coutre, Alberto Alvarez-Larrán, Carlo Gambacorti-Passerini, Susanne Saussele, Laura Antolini, Patrizia Pregno, Brian J. Druker

    المصدر: Blood. 136:21-22

    مصطلحات موضوعية: Oncology, medicine.medical_specialty, business.industry, medicine.drug_class, Immunology, Cell Biology, Hematology, Chronic phase chronic myeloid leukemia, Biochemistry, Tyrosine-kinase inhibitor, Discontinuation, Internal medicine, Medicine, Observational study, business, health care economics and organizations

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::1769964f55f9dd2c8b2210d93e3389dcTest
    https://doi.org/10.1182/blood-2020-140234Test


    أضف إلى المفضلة
  4. 54
    Impact of Comorbidities on Response Outcomes in Patients with Chronic Myeloid Leukemia in Chronic Phase Treated with First-Line Dasatinib Versus Imatinib: Exploratory Post Hoc Analysis of DASISION

    المؤلفون: Rene Swanink, Giuseppe Saglio, Elias Jabbour, Oumar Sy, Jorge E. Cortes, Philipp le Coutre, Michael J. Mauro, Antonio Jiménez-Velasco, Massimo Breccia, Wasiulla Khan, Irene DeGutis

    المصدر: Blood. 136:31-32

    مصطلحات موضوعية: medicine.medical_specialty, Proportional hazards model, business.industry, Immunology, Hazard ratio, Imatinib, Cell Biology, Hematology, medicine.disease, Biochemistry, Comorbidity, Discontinuation, Dasatinib, Internal medicine, Post-hoc analysis, medicine, Adverse effect, business, medicine.drug

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::9b8f208aeeac20475832a31d937339a6Test
    https://doi.org/10.1182/blood-2020-137636Test


    أضف إلى المفضلة
  5. 55
    Bosutinib (BOS) Versus Imatinib for Newly Diagnosed Chronic Phase (CP) Chronic Myeloid Leukemia (CML): Final 5-Year Results from the Bfore Trial

    المؤلفون: Andreas Hochhaus, Simon Purcell, Philippe Rousselot, Philipp le Coutre, Carlo Gambacorti-Passerini, Andrea Viqueira, Jeffrey H. Lipton, Michael W. Deininger, Rafael Hurtado Monroy, Michael J. Mauro, Richard E. Clark, Charles Chuah, Tim H. Brümmendorf, Anne Yver, Valentín García-Gutiérrez, Eric Leip, Vamsi Kota, Jorge E. Cortes, Dragana Milojkovic

    المصدر: Blood. 136:41-42

    مصطلحات موضوعية: Oncology, medicine.medical_specialty, business.industry, Immunology, Myeloid leukemia, Imatinib, Cell Biology, Hematology, Newly diagnosed, Biochemistry, Internal medicine, medicine, business, Bosutinib, medicine.drug

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::9d57860324bc709f6ca0f200ff99edf5Test
    https://doi.org/10.1182/blood-2020-137393Test


    أضف إلى المفضلة
  6. 56
    Long-Term Cardiac, Vascular, and Hypertension Safety of Bosutinib (BOS) Versus Imatinib (IMA) for Newly Diagnosed Chronic Myeloid Leukemia (CML): Results from the Bfore Trial

    المؤلفون: Carlo Gambacorti-Passerini, Simon Purcell, Vamsi Kota, Tim H. Brümmendorf, Jorge E. Cortes, Philipp le Coutre, Pia Raanani, Eric Leip, Valentín García-Gutiérrez, Andrea Viqueira, Henrik Hjorth-Hansen

    المصدر: Blood. 136:34-35

    مصطلحات موضوعية: medicine.medical_specialty, business.industry, MedDRA, Incidence (epidemiology), Immunology, Imatinib, Cell Biology, Hematology, Newly diagnosed, Biochemistry, Discontinuation, Internal medicine, Medicine, Risk factor, business, Adverse effect, Bosutinib, medicine.drug

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::17447b8b0d46b784726fa0a92b0ef72aTest
    https://doi.org/10.1182/blood-2020-134912Test


    أضف إلى المفضلة
  7. 57
    Efficacy and Safety of Front-Line Nilotinib Treatment and Discontinuation in Older Patients (≥65 years) with Chronic Myeloid Leukemia in Chronic Phase Who Have Achieved MR4.5: Results from ENESTfreedom

    المؤلفون: David M. Ross, Eibhlin Conneally, María Teresa Gómez Casares, Bruno Martino, Norbert Gattermann, Giuseppe Saglio, Jerald P. Radich, Andreas Hochhaus, Susanne Saussele, Ksenia Titorenko, Andrzej Hellmann, Sai Li, Tamás Masszi, Paola Aimone, Jesper Stentoft, Francis J. Giles, Jose Valentín García Gutiérrez, Philipp le Coutre

    المصدر: Blood. 136:7-8

    مصطلحات موضوعية: medicine.medical_specialty, business.industry, Immunology, Front line, Cell Biology, Hematology, Biochemistry, Discontinuation, Nilotinib, Older patients, Major Molecular Response, Family medicine, medicine, Current employment, business, medicine.drug

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::63cddfbb4d2e007c3b45680541ca53deTest
    https://doi.org/10.1182/blood-2020-137388Test


    أضف إلى المفضلة
  8. 58
    دورية أكاديمية
    Association of High Body Mass Index with Response Outcomes in Patients with CML-CP Treated with Dasatinib Versus Imatinib in the First Line: Exploratory Post Hoc Analysis of the Phase 3 DASISION Trial

    المؤلفون: Massimo Breccia, Jorge E. Cortes, Neil P Shah, Giuseppe Saglio, Antonio Jiménez-Velasco, Philipp Le Coutre, Alexander Brun, Irene DeGutis, Sai Bathena, Oumar Sy, Elias Jabbour

    المساهمون: Breccia, Massimo, Cortes, Jorge E., P Shah, Neil, Saglio, Giuseppe, Jiménez-Velasco, Antonio, Le Coutre, Philipp, Brun, Alexander, Degutis, Irene, Bathena, Sai, Sy, Oumar, Jabbour, Elias

    العلاقة: info:eu-repo/semantics/altIdentifier/wos/WOS:000577164602178; volume:134; issue:1; journal:BLOOD; https://hdl.handle.net/11573/1685341Test

    الإتاحة: https://doi.org/10.1182/blood-2019-121872Test
    https://hdl.handle.net/11573/1685341Test

    View record in BASE

    أضف إلى المفضلة
  9. 59
    Predictive significance of the European LeukemiaNet classification of genetic aberrations in patients with acute myeloid leukaemia undergoing allogeneic stem cell transplantation

    المؤلفون: Olaf Penack, Il-Kang Na, Christian Jehn, Philipp Hemmati, Bernd Dörken, Lam G. Vuong, Theis H. Terwey, Renate Arnold, Philipp le Coutre

    المصدر: European Journal of Haematology. 98:160-168

    مصطلحات موضوعية: Adult, Male, Oncology, medicine.medical_specialty, Transplantation Conditioning, Adolescent, Kaplan-Meier Estimate, Young Adult, 03 medical and health sciences, European LeukemiaNet, 0302 clinical medicine, Recurrence, Internal medicine, medicine, Humans, Transplantation, Homologous, In patient, Treatment Failure, Proportional Hazards Models, Retrospective Studies, Proportional hazards model, business.industry, Incidence (epidemiology), Hazard ratio, Hematopoietic Stem Cell Transplantation, Genetic Variation, Hematology, General Medicine, Middle Aged, Prognosis, Combined Modality Therapy, Surgery, Transplantation, Leukemia, Myeloid, Acute, Treatment Outcome, 030220 oncology & carcinogenesis, Female, Stem cell, Myeloid leukaemia, business, 030215 immunology

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c40267f08e9898e013543c8fb1c2eeb3Test
    https://doi.org/10.1111/ejh.12815Test


    أضف إلى المفضلة
  10. 60
    Efficacy and Safety of Asciminib, a Specific Allosteric BCR-ABL1 Inhibitor Targeting the Myristoyl-Binding Site, in Patients with Chronic Myeloid Leukemia (CML) Carrying the T315I Mutation

    المؤلفون: Timothy P. Hughes, Andreas Hochhaus, Massimo Breccia, Philipp le Coutre, Gabriel Etienne, Moshe Talpaz, Hironobu Minami, Kaushal Mishra, Fabian Lang, Jorge E. Cortes, Daniel J. DeAngelo, Dong-Wook Kim, Yeow Tee Goh, Michael W. Deininger, Delphine Rea, Manu Sondhi, Michael J. Mauro, Paola Aimone

    المصدر: Clinical Lymphoma Myeloma and Leukemia. 19:S289-S290

    مصطلحات موضوعية: Cancer Research, business.industry, Allosteric regulation, Myeloid leukemia, Hematology, T315i mutation, Bcr abl1, Oncology, Cancer research, Medicine, In patient, Binding site, business, Myristoylation

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::3376f826349e1c3e3b1f2f3a80ced94bTest
    https://doi.org/10.1016/j.clml.2019.07.234Test


    أضف إلى المفضلة
أدوات البحث: أحصل على تغذية RSS — أرسل هذا البحث بالبريد الإلكتروني — حفظ البحث